3 hours Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?The Motley Fool
On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies. After all, it’s been less than a year since r…
X